BioStock: PHI’s CEO comments on the approved US listing

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
Read the full interview with Patrik Eschricht on biostock.se.
Further reading

BioStock: PHI’s CEO reflects on global roadshow success
BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.

BioStock: PHI on how TO 3 proceeds will be used
BioStock talked to CEO Patrik Eschricht to learn how the TO 3 proceeds would be used.

BioStock: PHI´s CEO comments on latest advancements
BioStock reached out to PHI´s CEO, Patrik Eschricht, to learn more about the visions moving forward.

CERN seminar: The Promise of Regenerative Medicine and AI
During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.